Axovia Therapeutics
6 employees on LinkedIn · 2 known investors
Find your way into Axovia Therapeutics
375 people in our graph share verified history with the Axovia Therapeutics team — schools, employers, funds. One of them is your warm intro.
Saran Daviesunlockedknows Phil Beales · together at Congenica (overlapped)
knows the team · via UCL
knows the team · via University College London, Institute of Child Health
×8knows the team · via Universitat de Barcelona
knows the team · via Baylor College of Medicine
Axovia Therapeutics develops AAV9-based gene therapies for ciliopathies, a group of rare inherited genetic diseases, with a lead program targeting Bardet-Biedl Syndrome (BBS1) to prevent blindness and reverse obesity. A spin-off from University College London, its second program targets the most common genetic cause of obesity.
Founders & leadership
PB
Phil BealesinCo-founderPhil Beales is a physician-scientist and clinical geneticist with over 25 years in rare genetic disease research and rare disease care, known for contributions to Bardet-Biedl syndrome research including gene discovery and diagnostic criteria development, and founding a specialist NHS clinic for the condition; he is co-founder and CEO of Axovia Therapeutics, which develops gene therapies for ciliopathies and genetic disorders.
VH
Victor HernandezinCo-founder & Chief Scientific OfficerVictor Hernandez joined Professor Phil Beales' team at the Institute of Child Health, University College London in 2008 to study ciliopathies and genes involved in ciliary diseases, contributing research that informed understanding of disease biology and therapeutic development. He is now Co-founder and Chief Scientific Officer of Axovia Therapeutics, overseeing preclinical and toxicological research for gene therapies targeting ciliopathies, and holds a position as Lecturer in Biomedical Sciences at Brunel University London.
Investors · 2
Founder mafia
2 people who came through Axovia Therapeutics went on to found or lead other companies.
In the news
Frequently asked questions
- What does Axovia Therapeutics do?
- Axovia Therapeutics develops AAV9-based gene therapies for ciliopathies, a group of rare inherited genetic diseases, with a lead program targeting Bardet-Biedl Syndrome (BBS1) to prevent blindness and reverse obesity. A spin-off from University College London, its second program targets the most common genetic cause of obesity.
- Who founded Axovia Therapeutics?
- Axovia Therapeutics was founded by Phil Beales, Victor Hernandez.
- Who are Axovia Therapeutics's investors?
- Axovia Therapeutics's investors include AlbionVC, ALSA Ventures.